The objective the study is to determine 
Introduction
During the sacred month of Ramadan, people who fast neither eat nor drink from dawn to sunset. Many people with diabetes still prefer to fast, without medical guidance, exposing themselves to certain health risks as a direct consequence of fasting or because of a change in food and frequency of medication intake [1] . It is estimated that around 40 to 50 million individuals with diabetes worldwide fast during Ramadan [2] . In non-diabetic individuals, fasting is associated with improvement in several haemostatic risk markers for cardiovascular disease, including reduction in plasma triglyceride and plasma LDL-cholesterol level, as well as improvement in insulin sensitivity, leptin, adiponectin and HDL cholesterol [3] [4] [5] [6] .
Ramadan fasting in non-diabetic individuals is also associated with reduction in plasma homocysteine, D-dimer level, C-reactive protein (CRP) and IL-6 and fibrinogen. [7] [8] .
Similar beneficial effects of fasting have been reported in diabetic individuals. In a cohort of 276 obese women with type 2 diabetes, fasting during Ramadan was associated with decreased total calorie intake, weight reduction [9] and improvement in glucose homeostasis [10] . Recommendations for the management of diabetes during Ramadan were last published in 2005 by the American Diabetes Association. Several studies in this field have since been published, some addressing the use of new pharmacological agents in managing diabetes during Ramadan. The incretin mimetics are potentially safe during Ramadan; the DPP4 inhibitors vildagliptin and sitagliptin provide an effective and safe therapeutic option, administered either alone or in combination with metformin or sulfonylureas. There are no published studies on the use of GLP-1 receptor agonists during Ramadan. Among the sulfonylureas, gliclazide MR (modified release) and glimepride can be safely used during Ramadan, but glibenclamide should be avoided due to the associated risk of hypoglycemia. In selected patients with type 1 and type 2 diabetes, the long-acting insulin analogues glargine and detemir, as well as the premixed insulin analogues, can be used with minimal risk of metabolic derangement or hypoglycemia; the risk is higher in type 1 diabetes. Insulin pumps can potentially empower patients with diabetes and enable safe fasting during the month of Ramadan [11] . When we take food insulin is released from beta-cells of pancreas to utilize fuel taken for instant energy production and subsequently to promote storage of fuel as glycogen and fat in muscle, liver, and adipose tissue. During the fasting state due to glucagon and other counter-regulatory hormones and low insulin secretion, there is release of glucose by increased hepatic glucose output and release of fatty acids from adipose tissue to supply 
Materials and Methods
This is a observational prospective study. A convenient sampling method is used to select the study population. Hospital ethical review committee approval has taken after explaining to them in detail the protocols and purposes of the research. All patients with well-controlled Patients were kept on the same drug regimen, they were on before Ramadan. Only their dosages were changed according to the Ramadan Guidelines provided by Diabetes and 
Results
The study included a total 0f 30 subjects, of which 14(46.7%) were male and 16(53.3%) were female. Out of 30(100%) subjects, 25(83.3%) had no hypoglycemia, 4(13.3%) had 1 episode of hypoglycemia and 1(3.3%) had 2 episodes of hypoglycemia. (Figure 1 ).
Figure 1. Number of Hypoglycemia
Out of 30(100%) subjects, 24(80.0%) never needed to break a fast, 5(16.7%) had 1 event of breaking the fast and 1(3.3%) had 2 events of breaking the fast. There was 1 event of missing the fast in 2(6.7%) patients. Out of 30(100%) subjects, 8 (26.7%) patients were on insulin alone, 8(26.7%) were on insulin and oral hypoglycemics combination, 4(13.4%) were on single oral hypoglycemics, 7(23.3%) were on combination oral hypoglycemic and 3(10%)
were on lifestyle modification (Table 1) .
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Fasting This can be reduced by using basal insulin analogs such as insulin detemir or glargine, or rapid acting insulin analogs such as aspart, lispro, or glulisine [12] .
Conclusion and Recommendations
Fasting in type 2 diabetes mellitus patients is usually safe if proper cautions are observed.
Muslims with diabetes willing to fast should be educated about individually tailored diet plan before Ramadan and also the possible hazards. They should be in contact with their attending physician. During the fast for appropriate advice in the event of any complication (like hypo/hyperglycemia. Any possible contraindications should be identified before the start of Ramadan and they should be forbidden to fast if necessary. All commonly used antidiabetic drugs are safe if used wisely and under intensive monitoring. Drug regimens and dosages should be adjusted according to Ramadhan guidelines so as to decrease the incidence of hypoglycemia and hyperglycemia.
As our sample size is small so we recommend for concrete conclusion; we recommend further studies with larger sample size.
